Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ginkgo Biloba Extract for Preventing Cognitive Decline in the Oldest Old
NCT00010920Phase 3
Key facts
- Status
- Completed
- Start
- Sep 1999
- Countries
- 1
- Sponsor
- National Center for Complementary and Integrative Health
- Modality
- Small Molecules
- Conditions
- DementiaMild Cognitive Impairment (MCI)
01
Overview
Phase 3, randomised, double-blind trial in Dementia and Mild Cognitive Impairment (MCI) comparing Ginkgo Biloba Extract with Placebo (2 arms). Primary endpoint: Conversion to Mild Cognitive Impairment at 42 months. Started Sep 1999; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Ginkgo Biloba Extract
Standardized Ginkgo Biloba Extract
Placebo
Placebo control
03
Endpoints
Primary
Conversion to Mild Cognitive Impairment
Secondary
Decrease in brain volume loss
Beyond the preview
Go deeper on NCT00010920.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00010920.